Progression of Hematopoietic Diseases in Shanghai, China
NCT ID: NCT00365014
Last Updated: 2013-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
10757 participants
OBSERVATIONAL
2003-08-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia
NCT07019766
Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia
NCT06378060
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
NCT02338479
Critical Illness After Hematopoietic Cell Transplantation
NCT07328724
Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador
NCT05825326
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Blood disease patients
People with blood diseases presenting at Shanghai hospitals
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
University of Cincinnati
OTHER
ExxonMobil Biomedical Sciences, Inc.
INDUSTRY
British Petroleum P.L.C.
INDUSTRY
Chevron Corporation
INDUSTRY
ConocoPhillips
INDUSTRY
Exxon Mobil
INDUSTRY
Marathon Ashland
UNKNOWN
Shell Chemicals
INDUSTRY
University of Colorado, Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard D Irons, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Colorado at Denver and Health Sciences Ctr.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Joint Sino-US Clinical and Molecular Laboratory (JCML)
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
02-0036
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.